Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) shares were down 2.8% during mid-day trading on Thursday . The company traded as low as $12.20 and last traded at $12.35, with a volume of 69,666 shares changing hands. The stock had previously closed at $12.70.

Separately, Zacks Investment Research downgraded Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th.

The stock’s 50-day moving average price is $11.30 and its 200 day moving average price is $10.12. The company’s market capitalization is $132.99 million.

Dipexium Pharmaceuticals (NASDAQ:DPRX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. On average, analysts predict that Dipexium Pharmaceuticals Inc. will post ($2.10) EPS for the current fiscal year.

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.